Latelines for Aug. 18, 2003
Roflumilast Foam Improves Symptoms of Scalp, Body Psoriasis
The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.
Demystifying PBMs, Their Role in the Drug Supply Chain
President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.
Tremfya Demonstrates Sustained Response Up to 92 Weeks
Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.
Scripted for Her: Helping Patients Choose Contraceptive Methods
In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.
Bemnifosbuvir, Ruzasvir Regimen Shows Strong Efficacy as HCV Treatment
A phase 2 study found 95% of patients achieved a sustained virologic response at 12 weeks regardless of treatment adherence.
FDA Grants Ustekinumab-Aekn Interchangeability Designation for Stelara
Selarsdi is interchangeable for all indications of ustekinumab, including treatment of psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.
